Tag: metastatic castration‑sensitive prostate cancer

Home / metastatic castration‑sensitive prostate cancer

Categories

Darolutamide is approved by the USFDA for metastatic castration-sensitive prostate cancer

On June 3, 2025, the Food and Drug Administration (FDA) sanctioned darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA has...
metastatic-castration%E2%80%91sensitive-prostate-cancer

Scan the code